The booming popularity of Ozempic and other GLP-1 drugs for weight loss has led to a flurry of companies vying to make new and improved anti-obesity medications .

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual surgery required. Today, the company announced early data from animals and a small group of human volunteers showing that its approach is safe and may be able to suppress hunger. The company presented the findings Thursday at the European Congress on Obesity and Weight Management.

“We're at a stage with obesity treatment where it's important for us to figure out, how do we now tune it to be more effective?” says Rahul Dhanda, Syntis Bio’s CEO and cofounder.

Read full article

Comments

The booming popularity of Ozempic and other GLP-1 drugs for weight loss has led to a flurry of companies vying to make new and improved anti-obesity medications .

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual surgery required. Today, the company announced early data from animals and a small group of human volunteers showing that its approach is safe and may be able to suppress hunger. The company presented the findings Thursday at the European Congress on Obesity and Weight Management.

“We're at a stage with obesity treatment where it's important for us to figure out, how do we now tune it to be more effective?” says Rahul Dhanda, Syntis Bio’s CEO and cofounder.

Read full article

Comments

The booming popularity of Ozempic and other GLP-1 drugs for weight loss has led to a flurry of companies vying to make new and improved anti-obesity medications .

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual surgery required. Today, the company announced early data from animals and a small group of human volunteers showing that its approach is safe and may be able to suppress hunger. The company presented the findings Thursday at the European Congress on Obesity and Weight Management.

“We're at a stage with obesity treatment where it's important for us to figure out, how do we now tune it to be more effective?” says Rahul Dhanda, Syntis Bio’s CEO and cofounder.

Read full article

Comments